Purchase this article with an account.
M. M. Moschos, A. Triglianos, P. Minogiannis, I. Markopoulos, M. Apostolopoulos, M. Moschos; Intraocular Bevacizumab for Macular Edema Due to Crvo. A Multifocal-Erg and Oct Study. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3287.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate by mfERG and OCT the effectiveness of intravitreal use of bevacizumab (Avastin) in the treatment of macular edema due to central retinal vein occlusion (CRVO).
Before treatment, OCT shows an increase of the retinal thickness of the fovea. One and 3 months after treatment the foveal thickness decreased to a significant level. The electrical responses in the fovea and parafovea of the mfERG recording depicted a significant improvement at 1 and 3 months after the injection. No patient manifested intraocular pressure increase.
The intravitreal use of bevacizumab may provide anatomical and functional amelioration of the macula in patients with macular edema due to CRVO. However, further study is needed in order to assess the treatment's long-term efficacy.
This PDF is available to Subscribers Only